The purpose of this study is to determine whether hydroxychloroquine is an effective prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants will be randomized into two parallel groups. The first arm will evaluate the use of hydroxychloroquine every-other-day plus standard measures of protection for the prevention of SARS-CoV-2. The second arm will evaluate the use of standard measures of protection for the prevention of SARS-CoV-2. The target enrollment is 320 participants. Each study participant will be monitored for SARS-CoV-2 seroconversion in weekly visits or for the development of COVID-19 symptoms for 8 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
68
A loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.
Centro Médico Naval "Cirujano Mayor Santiago Távara"
Callao, Peru
Hospital Nacional Arzobispo Loayza
Lima, Peru
Hospital Cayetano Heredia
Lima, Peru
Efficacy: Proportion of participants with positive molecular or serologic testing for SARS-CoV-2
Time frame: Eight weeks
Safety: Proportion of participants with grade 3 or more adverse events
Time frame: Eight weeks
Tolerability: Proportion of participants that discontinue prophylactic treatment due to grade 1 or 2 adverse events
Time frame: Eight weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.